{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:37Z","timestamp":1789506337312,"version":"build-2803163510"},"publisher-location":"New York, NY","reference-count":67,"publisher":"Springer US","isbn-type":[{"value":"9781071641958","type":"print"},{"value":"9781071641965","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4196-5_11","type":"book-chapter","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:42:40Z","timestamp":1732254160000},"page":"185-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Structural and Functional Studies on HIV Protease: Mechanism of Action, Subtypes, Inhibitors, and Drug Resistance"],"prefix":"10.1007","author":[{"given":"Sankaran","family":"Venkatachalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya Ramaswamy","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasien","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Michael","family":"Gromiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"issue":"4599","key":"11_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.6189183","volume":"220","author":"F Barr\u00e9-Sinoussi","year":"1983","unstructured":"Barr\u00e9-Sinoussi F, Chermann JC, Rey F et al (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599):868\u2013871","journal-title":"Science"},{"issue":"4599","key":"11_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.6601823","volume":"220","author":"RC Gallo","year":"1983","unstructured":"Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M et al (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220(4599):865\u2013867","journal-title":"Science"},{"issue":"1","key":"11_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006841","volume":"1","author":"PM Sharp","year":"2011","unstructured":"Sharp PM, Hahn BH (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1(1):a006841","journal-title":"Cold Spring Harb Perspect Med"},{"key":"11_CR4","unstructured":"Haacker M (2004) The demographic impact of HIV\/AIDS. In: The macroeconomics of HIV\/AIDSUSA, International Monetary Fund. Available via DIALOG. https:\/\/www.elibrary.imf.org\/display\/book\/9781589063600\/ch01.xml. Accessed 17 May 2024"},{"key":"11_CR5","unstructured":"Joint United Nations Programme on HIV\/Aids (UNAIDS) (2022) Global HIV & AIDS statistics-Factssheet. https:\/\/www.unaids.org\/en\/resources\/fact sheet#:~:text=39%20million%20%5B33.1%20million%E2%80%9345.7,AIDS%2Drelated%20illnesses%20in%202022. Accessed 15 Sept 2024"},{"key":"11_CR6","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996) Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans, France"},{"issue":"4","key":"11_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/rmv.1739","volume":"23","author":"S Nyamweya","year":"2013","unstructured":"Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S et al (2013) Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol 23(4):221\u2013240","journal-title":"Rev Med Virol"},{"issue":"7","key":"11_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0092-8674(00)81313-6","volume":"85","author":"H Choe","year":"1996","unstructured":"Choe H, Farzan M, Sun Y, Sullivan N, Rollins B et al (1996) The \u03b2-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85(7):1135\u20131148","journal-title":"Cell"},{"issue":"32","key":"11_CR9","doi-asserted-by":"publisher","first-page":"19771","DOI":"10.1074\/jbc.272.32.19771","volume":"272","author":"G Alkhatib","year":"1997","unstructured":"Alkhatib G, Ahuja SS, Light D, Mummidi S, Berger EA, Ahuja SK (1997) CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants: critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem 272(32):19771\u201319776","journal-title":"J Biol Chem"},{"issue":"1","key":"11_CR10","first-page":"14","volume":"19","author":"EK Maina","year":"2021","unstructured":"Maina EK, Adan AA, Mureithi H, Muriuki J et al (2021) A review of current strategies towards the elimination of latent HIV-1 and subsequent HIV-1 cure. Curr HIV Res 19(1):14\u201326","journal-title":"Curr HIV Res"},{"issue":"13","key":"11_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2174\/1568026033451781","volume":"3","author":"J Tozser","year":"2003","unstructured":"Tozser J (2003) Stages of HIV replication and targets for therapeutic intervention. Curr Top Med Chem 3(13):1447\u20131457","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"11_CR12","first-page":"15","volume":"18","author":"DY Lu","year":"2018","unstructured":"Lu DY, Wu HY, Yarla NS, Xu B et al (2018) HAART in HIV\/AIDS treatments: future trends. Infect Disord Drug Targets (Formerly Current Drug Targets-Infectious Disorders) 18(1):15\u201322","journal-title":"Infect Disord Drug Targets (Formerly Current Drug Targets-Infectious Disorders)"},{"key":"11_CR13","volume-title":"StatPearls","author":"JS Eggleton","year":"2023","unstructured":"Eggleton JS, Nagalli S (2023) Highly active antiretroviral therapy (HAART). In: StatPearls. StatPearls Publishing"},{"issue":"12","key":"11_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks SG, Archin N, Cannon P, Collins S, Jones RB et al (2021) Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med 27(12):2085\u20132098","journal-title":"Nat Med"},{"issue":"1","key":"11_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","volume":"85","author":"AM Wensing","year":"2010","unstructured":"Wensing AM, van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antivir Res 85(1):59\u201374","journal-title":"Antivir Res"},{"issue":"6","key":"11_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0735-0651(88)90010-6","volume":"5","author":"TD Copeland","year":"1988","unstructured":"Copeland TD, Oroszlan S (1988) Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene Anal Tech 5(6):109\u2013115","journal-title":"Gene Anal Tech"},{"issue":"6153","key":"11_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/331280a0","volume":"331","author":"T Jacks","year":"1988","unstructured":"Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE (1988) Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331(6153):280\u2013283","journal-title":"Nature"},{"issue":"5","key":"11_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/v13050839","volume":"13","author":"IT Weber","year":"2021","unstructured":"Weber IT, Wang YF, Harrison RW (2021) HIV protease: historical perspective and current research. Viruses 13(5):839","journal-title":"Viruses"},{"issue":"3\u20134","key":"11_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1600-0684.1990.tb00446.x","volume":"19","author":"LE Henderson","year":"1990","unstructured":"Henderson LE, Sowder RC, Copeland TD, Oroszlan S, Benveniste RE (1990) Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions. J Med Primatol 19(3\u20134):411\u2013419","journal-title":"J Med Primatol"},{"issue":"9534","key":"11_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","volume":"368","author":"V Simon","year":"2006","unstructured":"Simon V, Ho DD, Karim QA (2006) HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368(9534):489\u2013504","journal-title":"Lancet"},{"issue":"5","key":"11_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.coviro.2012.08.006","volume":"2","author":"RJ Lessells","year":"2012","unstructured":"Lessells RJ, Katzenstein DK, De Oliveira T (2012) Are subtype differences important in HIV drug resistance? Curr Opin Virol 2(5):636\u2013643","journal-title":"Curr Opin Virol"},{"issue":"4","key":"11_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jmb.2007.03.049","volume":"369","author":"M Sanches","year":"2007","unstructured":"Sanches M, Krauchenco S, Martins NH, Gustchina A, Wlodawer A, Polikarpov I (2007) Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J Mol Biol 369(4):1029\u20131040","journal-title":"J Mol Biol"},{"issue":"2","key":"11_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0014-5793(91)80328-Z","volume":"280","author":"EM Wondrak","year":"1991","unstructured":"Wondrak EM, Louis JM, Mora PT, Oroszlan S (1991) Purification of HIV-1 wild-type protease and characterization of proteolytically inactive HIV-1 protease mutants by pepstatin A affinity chromatography. FEBS Lett 280(2):347\u2013350","journal-title":"FEBS Lett"},{"issue":"1","key":"11_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0006-291X(89)92408-X","volume":"159","author":"JM Louis","year":"1989","unstructured":"Louis JM, Wondrak EM, Copeland TD, Smith CD, Mora PT, Oroszlan S (1989) Chemical synthesis and expression of the HIV-1 protease gene in Ecoli. Biochem Biophys Res Commun 159(1):87\u201394","journal-title":"Biochem Biophys Res Commun"},{"issue":"6247","key":"11_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/342299a0","volume":"342","author":"R Lapatto","year":"1989","unstructured":"Lapatto R, Blundell T, Hemmings A, Overington J, Wilderspin A, Wood S et al (1989) X-ray analysis of HIV-1 proteinase at 2.7 \u00c5 resolution confirms structural homology among retroviral enzymes. Nature 342(6247):299\u2013302","journal-title":"Nature"},{"issue":"4918","key":"11_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1126\/science.2548279","volume":"245","author":"A Wlodawer","year":"1989","unstructured":"Wlodawer A, Miller M, Jask\u00f3lski M, Sathyanarayana BK, Baldwin E et al (1989) Conserved folding in retroviral proteases: crystal structure of synthetic HIV-1 protease. Science 245(4918):616\u2013621","journal-title":"Science"},{"issue":"6208","key":"11_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/337615a0","volume":"337","author":"MA Navia","year":"1989","unstructured":"Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK et al (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337(6208):615\u2013620","journal-title":"Nature"},{"issue":"11","key":"11_CR28","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/j.1432-1033.2004.04136.x","volume":"271","author":"I Simoes","year":"2004","unstructured":"Simoes I, Faro C (2004) Structure and function of plant aspartic proteinases. Eur J Biochem 271(11):2067\u20132075","journal-title":"Eur J Biochem"},{"key":"11_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2021.107931","volume":"106","author":"D Sherry","year":"2021","unstructured":"Sherry D, Worth R, Ismail ZS, Sayed Y (2021) Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: implications for flap dynamics. J Mol Graph Model 106:107931","journal-title":"J Mol Graph Model"},{"issue":"5614","key":"11_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/267808a0","volume":"267","author":"MN James","year":"1977","unstructured":"James MN, Hsu IN, Delbaere LT (1977) Mechanism of acid protease catalysis based on the crystal structure of penicillopepsin. Nature 267(5614):808\u2013813","journal-title":"Nature"},{"issue":"46","key":"11_CR31","doi-asserted-by":"publisher","first-page":"E9855","DOI":"10.1073\/pnas.1716098114","volume":"114","author":"L Deshmukh","year":"2017","unstructured":"Deshmukh L, Tugarinov V, Louis JM, Clore GM (2017) Binding kinetics and substrate selectivity in HIV-1 protease\u2212Gag interactions probed at atomic resolution by chemical exchange NMR. Proc Natl Acad Sci 114(46):E9855\u2013E9862","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"11_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","volume":"10","author":"M Prabu-Jeyabalan","year":"2002","unstructured":"Prabu-Jeyabalan M, Nalivaika E, Schiffer CA (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10(3):369\u2013381","journal-title":"Structure"},{"issue":"12","key":"11_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0969-2126(00)00537-2","volume":"8","author":"WR Scott","year":"2000","unstructured":"Scott WR, Schiffer CA (2000) Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 8(12):1259\u20131265","journal-title":"Structure"},{"issue":"2","key":"11_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1110\/ps.33202","volume":"11","author":"DI Freedberg","year":"2002","unstructured":"Freedberg DI, Ishima R, Jacob J, Wang YX, Kustanovich I, Louis JM, Torchia DA (2002) Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci 11(2):221\u2013232","journal-title":"Protein Sci"},{"issue":"71","key":"11_CR35","doi-asserted-by":"publisher","first-page":"45121","DOI":"10.1039\/C7RA09691G","volume":"7","author":"Y Yu","year":"2017","unstructured":"Yu Y, Wang J, Chen Z, Wang G, Shao Q, Shi J, Zhu W (2017) Structural insights into HIV-1 protease flap opening processes and key intermediates. RSC Adv 7(71):45121\u201345128","journal-title":"RSC Adv"},{"issue":"1","key":"11_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-5793(90)81171-J","volume":"269","author":"A Gustchina","year":"1990","unstructured":"Gustchina A, Weber IT (1990) Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap. FEBS Lett 269(1):269\u2013272","journal-title":"FEBS Lett"},{"issue":"1","key":"11_CR37","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/s41598-020-62423-y","volume":"10","author":"A Badaya","year":"2020","unstructured":"Badaya A, Sasidhar YU (2020) Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations. Sci Rep 10(1):5501","journal-title":"Sci Rep"},{"key":"11_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.crstbi.2024.100132","volume":"7","author":"SV Sankaran","year":"2024","unstructured":"Sankaran SV, Krishnan SR, Sayed Y, Gromiha MM (2024) Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir. Curr Res Struct Biol 7:100132","journal-title":"Curr Res Struct Biol"},{"issue":"Suppl 1","key":"11_CR39","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.4081\/idr.2013.s1.e5","volume":"5","author":"PS Pennings","year":"2013","unstructured":"Pennings PS (2013) HIV drug resistance: problems and perspectives. Infect Dis Rep 5(Suppl 1):e5","journal-title":"Infect Dis Rep"},{"issue":"5","key":"11_CR40","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1128\/AAC.49.5.2015-2025.2005","volume":"49","author":"V Svicher","year":"2005","unstructured":"Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellocchi MC et al (2005) Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 49(5):2015\u20132025","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"11_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S0042-6822(03)00484-7","volume":"314","author":"NG Hoffman","year":"2003","unstructured":"Hoffman NG, Schiffer CA, Swanstrom R (2003) Covariation of amino acid positions in HIV-1 protease. Virology 314(2):536\u2013548","journal-title":"Virology"},{"key":"11_CR42","first-page":"210","volume-title":"Protein mutations: consequence on structure, function and diseases","author":"SV Sankaran","year":"2024","unstructured":"Sankaran SV, Phogat A, Gromiha MM (2024) Computational resources for understanding disease-causing mutations in proteins: applications to HIV. In: Gromiha MM (ed) Protein mutations: consequence on structure, function and diseases. World Scientific, Singapore, pp 210\u2013228"},{"issue":"8","key":"11_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1096\/fasebj.10.8.8666162","volume":"10","author":"E Domingo","year":"1996","unstructured":"Domingo E, Escarm\u00eds C, Sevilla N, Moya A, Elena SF, Quer J, Holland JJ (1996) Basic concepts in RNA virus evolution. FASEB J 10(8):859\u2013864","journal-title":"FASEB J"},{"issue":"5","key":"11_CR44","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1073\/pnas.94.5.1862","volume":"94","author":"AJL Brown","year":"1997","unstructured":"Brown AJL (1997) Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci 94(5):1862\u20131865","journal-title":"Proc Natl Acad Sci"},{"issue":"24","key":"11_CR45","doi-asserted-by":"publisher","first-page":"14441","DOI":"10.1073\/pnas.95.24.14441","volume":"95","author":"M Nijhuis","year":"1998","unstructured":"Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J (1998) Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci 95(24):14441\u201314446","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"11_CR46","first-page":"62","volume":"16","author":"VA Johnson","year":"2008","unstructured":"Johnson VA, Brun-V\u00e9zinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Richman DD (2008) Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 16(1):62\u201368","journal-title":"Top HIV Med"},{"issue":"18","key":"11_CR47","doi-asserted-by":"publisher","first-page":"8524","DOI":"10.1128\/JVI.74.18.8524-8531.2000","volume":"74","author":"F Mammano","year":"2000","unstructured":"Mammano F, Trouplin V, Zennou V, Clavel F (2000) Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 74(18):8524\u20138531","journal-title":"J Virol"},{"issue":"9","key":"11_CR48","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","volume":"72","author":"F Mammano","year":"1998","unstructured":"Mammano F, Petit C, Clavel F (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 72(9):7632\u20137637","journal-title":"J Virol"},{"issue":"17","key":"11_CR49","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1097\/00002030-199912030-00006","volume":"13","author":"M Nijhuis","year":"1999","unstructured":"Nijhuis M, Schuurman R, De Jong D, Erickson J, Gustchina E, Albert J, Boucher CA (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13(17):2349\u20132359","journal-title":"AIDS"},{"issue":"2","key":"11_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/cbdd.12063","volume":"81","author":"SM Ahmed","year":"2013","unstructured":"Ahmed SM, Kruger HG, Govender T, Maguire GE, Sayed Y, Ibrahim MA, Soliman ME (2013) Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR. Chem Biol Drug Des 81(2):208\u2013218","journal-title":"Chem Biol Drug Des"},{"issue":"10","key":"11_CR51","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1515\/hsz-2017-0107","volume":"398","author":"SB Maseko","year":"2017","unstructured":"Maseko SB, Padayachee E, Govender T, Sayed Y, Kruger G, Maguire GE, Lin J (2017) I36T\u2191 T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions. Biol Chem 398(10):1109\u20131117","journal-title":"Biol Chem"},{"issue":"2","key":"11_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/genes14020533","volume":"14","author":"S Venkatachalam","year":"2023","unstructured":"Venkatachalam S, Murlidharan N, Krishnan SR, Ramakrishnan C, Setshedi M, Pandian R, Gromiha MM (2023) Understanding drug resistance of wild-type and L38HL insertion mutant of HIV-1 C protease to Saquinavir. Genes 14(2):533","journal-title":"Genes"},{"issue":"6","key":"11_CR53","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1128\/jvi.70.6.3763-3769.1996","volume":"70","author":"L Doyon","year":"1996","unstructured":"Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70(6):3763\u20133769","journal-title":"J Virol"},{"issue":"11","key":"11_CR54","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1016\/j.ejmech.2009.05.016","volume":"44","author":"EFF da Cunha","year":"2009","unstructured":"da Cunha EFF, Sippl W, de Castro RT, Antunes OAC, de Alencastro RB, Albuquerque MG (2009) 3D-QSAR CoMFA\/CoMSIA models based on theoretical active conformers of HOE\/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. Eur J Med Chem 44(11):4344\u20134352","journal-title":"Eur J Med Chem"},{"key":"11_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1023\/A:1023888813526","volume":"16","author":"W Sippl","year":"2002","unstructured":"Sippl W (2002) Development of biologically active compounds by combining 3D QSAR and structure-based design methods. J Comput Aided Mol Des 16:825\u2013830","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"11_CR56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/156802610790232260","volume":"10","author":"J Verma","year":"2010","unstructured":"Verma J, Khedkar VM, Coutinho EC (2010) 3D-QSAR in drug design-a review. Curr Top Med Chem 10(1):95\u2013115","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"11_CR57","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/1568026023392887","volume":"2","author":"M Akamatsu","year":"2002","unstructured":"Akamatsu M (2002) Current state and perspectives of 3D-QSAR. Curr Top Med Chem 2(12):1381\u20131394","journal-title":"Curr Top Med Chem"},{"issue":"9","key":"11_CR58","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17460441.2020.1773428","volume":"15","author":"FA Olotu","year":"2020","unstructured":"Olotu FA, Agoni C, Soremekun O, Soliman ME (2020) The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery. Expert Opin Drug Discov 15(9):1095\u20131109","journal-title":"Expert Opin Drug Discov"},{"key":"11_CR59","first-page":"1","volume":"2","author":"K Ojha Lokendra","year":"2013","unstructured":"Ojha Lokendra K, Rachana S, Rani BM (2013) Modern drug design with advancement in QSAR: a review. Int J Res Biosci 2:1\u201312","journal-title":"Int J Res Biosci"},{"issue":"2","key":"11_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/157340611794859370","volume":"7","author":"GL Ferreira","year":"2011","unstructured":"Ferreira GL, Leitao A, Montanari AC, Andricopulo DA (2011) Comparative molecular field analysis of a series of inhibitors of HIV-1 protease. Med Chem 7(2):71\u201379","journal-title":"Med Chem"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-153X-7-88","volume":"7","author":"Z Ul-Haq","year":"2013","unstructured":"Ul-Haq Z, Usmani S, Shamshad H, Mahmood U, Halim SA (2013) A combined 3D-QSAR and docking studies for the In-silico prediction of HIV-protease inhibitors. Chem Cent J 7:1\u201312","journal-title":"Chem Cent J"},{"issue":"2","key":"11_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1021\/jm0102710","volume":"45","author":"X Huang","year":"2002","unstructured":"Huang X, Xu L, Luo X, Fan K, Ji R, Pei G, Jiang H (2002) Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J Med Chem 45(2):333\u2013343","journal-title":"J Med Chem"},{"issue":"23","key":"11_CR63","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1016\/j.bmcl.2008.09.107","volume":"18","author":"S Durdagi","year":"2008","unstructured":"Durdagi S, Mavromoustakos T, Papadopoulos MG (2008) 3D QSAR CoMFA\/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. Bioorg Med Chem Lett 18(23):6283\u20136289","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"11_CR64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ardp.200700229","volume":"341","author":"P Nunthanavanit","year":"2008","unstructured":"Nunthanavanit P, Anthony NG, Johnston BF, Mackay SP, Ungwitayatorn J (2008) 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis. Archiv der Pharmazie Int J Pharm Med Chem 341(6):357\u2013364","journal-title":"Archiv der Pharmazie Int J Pharm Med Chem"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molstruc.2016.09.052","volume":"1129","author":"J Tong","year":"2017","unstructured":"Tong J, Wu Y, Bai M, Zhan P (2017) 3D-QSAR and molecular docking studies on HIV protease inhibitors. J Mol Struct 1129:17\u201322","journal-title":"J Mol Struct"},{"issue":"5","key":"11_CR66","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/1062936X.2018.1447511","volume":"29","author":"SA Amin","year":"2018","unstructured":"Amin SA, Adhikari N, Bhargava S, Jha T, Gayen S (2018) Structural exploration of hydroxyethylamines as HIV-1 protease inhibitors: new features identified. SAR QSAR Environ Res 29(5):385\u2013408","journal-title":"SAR QSAR Environ Res"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"581","DOI":"10.4172\/2155-6113.1000581","volume":"7","author":"JD Baxter","year":"2016","unstructured":"Baxter JD, Chasanov WM, Adams JL (2016) An update on HIV-1 protease inhibitor resistance. J AIDS Clin Res 7:581","journal-title":"J AIDS Clin Res"}],"container-title":["Methods in Molecular Biology","Prediction of Protein Secondary Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4196-5_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:23:15Z","timestamp":1732256595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4196-5_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"ISBN":["9781071641958","9781071641965"],"references-count":67,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4196-5_11","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"23 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}